Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Financial Group Inc (AFG) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance

American Financial Group Inc
Amphastar Pharmaceuticals Inc

Price performance

Price movement over the last 24 hours

Key statistics

American Financial Group Inc vs Amphastar Pharmaceuticals Inc — how do they compare? American Financial Group Inc trades at $141.21 (market cap $11.86B), while Amphastar Pharmaceuticals Inc trades at $18.81 (market cap $885.83M). The key difference: American Financial Group Inc is far larger — about 13.4× Amphastar Pharmaceuticals Inc's market cap, and American Financial Group Inc pays a 2.46% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AFGAMPH
Market Cap
$11.86B$885.83M
Sector
FinancialsHealth
52-Week High
$148.71$30.81
52-Week Low
$122.42$16.87
Enterprise Value
$12.33B$1.28B
Dividend Yield
2.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Financial Group Inc

AFG trades at $142.80, up 0.04% with a bullish technical outlook. The stock shows strong profitability with 10.84% net margin and 19.38% ROE, though Q1 2026 earnings missed estimates. Recent dividend declarations of $0.88 per share highlight shareholder returns. Analyst consensus is mixed with 41% buy ratings and a $149 price target, representing 4.3% upside from current levels.

AFG offers moderate upside potential with solid fundamentals and consistent dividends, but faces execution risks after recent earnings miss. The insurance sector exposure provides stability, though competitive pressures and regulatory changes remain key watchpoints for investors seeking steady returns with income generation.

Amphastar Pharmaceuticals Inc

AMPH trades at $19.61, down 0.15% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 11.81 and net margin of 11%, but recent earnings misses and declining 2026 profit projections raise concerns. Recent news includes a Zacks Strong Sell rating and a securities law investigation, while management focuses on transitioning to proprietary drugs for growth.

The outlook remains cautious with analyst consensus at Hold (66.7%) and a $20.40 price target offering limited upside. Key risks include earnings volatility, competitive pressures, and legal scrutiny. The stock presents moderate value but requires careful monitoring of execution on growth initiatives and upcoming Q2 earnings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Financial Group Inc

American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.

Read more on AFG

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH